Owen R T
Drugs Today (Barc). 2011 Jul;47(7):531-7. doi: 10.1358/dot.2011.47.7.1622076.
Vilazodone hydrochloride belongs to a new class of antidepressants-the indolalkylamines-and has dual activity as a selective serotonin reuptake inhibitor (SSRI) and as a partial agonist of the serotonin 5-HT(1A) receptor. Its antidepressant activity has been demonstrated in two 8-week, double-blind, randomized, placebo-controlled trials and in a 1-year open-label study. None of these trials compared vilazodone with existing antidepressants; however, changes in depressive symptoms after vilazodone treatment were similar to those reported for SSRIs. The most common adverse events were diarrhea and nausea, although these were mild to moderate in severity and rarely a cause for discontinuation. No important clinical changes in vital signs, laboratory values, ECG morphology and sexual function were observed or reported.
盐酸维拉佐酮属于一类新型抗抑郁药——吲哚烷基胺类——具有双重活性，既是选择性5-羟色胺再摄取抑制剂（SSRI），又是5-羟色胺5-HT(1A)受体的部分激动剂。其抗抑郁活性已在两项为期8周的双盲、随机、安慰剂对照试验以及一项为期1年的开放标签研究中得到证实。这些试验均未将维拉佐酮与现有抗抑郁药进行比较；然而，维拉佐酮治疗后抑郁症状的变化与SSRI类药物报道的情况相似。最常见的不良事件为腹泻和恶心，不过其严重程度为轻至中度，很少导致停药。未观察到或报道生命体征、实验室检查值、心电图形态及性功能有重要临床变化。
